National EMS Memorial Service Honoree
Mario Santoro New York Presbyterian Hospital New York, New York
When the first aircraft hit the north tower of the World Trade Center, Mario Santoro and his partner were the first emergency medical team assigned to the scene. They were stationed at Church and Fulton Streets. On site the team immediately started treating the numerous patients that were exiting the tower. When the second aircraft hit the south tower they entered it to reach patients and began treatment. When the tower came crashing to the ground all communication with the team was lost.
"They treated the injured and directed other ambulance crews to the place they were needed most. This is the first time in the history of our department where a crew has not come home�It has been a very difficult time," stated co-worker Brian Washburn. Santoro is one of the team dubbed the "elite eight".
Mario Santoro was employed with New York Presbyterian Hospital in New York City, New York as an advanced emergency medical worker. He lost his life when the World Trade Center fell to the ground caused by the terrorist attacks of September 11, 2001. Prior to working with Presbyterian Mario was employed with MetroCare Ambulance.
Honored 2002
Tuesday, November 3, 2009
Keith Fairben
National EMS Memorial Service Honoree
Keith Fairben New York Presbyterian Hospital New York, New York
As a father looks diligently through the rubble of the fallen World Trade Center, tears fall from the eyes of those around him. They can only grieve as they feel a small part of the pain he must feel within. The father, a volunteer firefighter for 32 years, is searching though the giant heap of twisted metal and sacred dust for a reason. He is looking for a victim lost in the fallen Twin Towers; however, not just any victim, he is looking for his only child, his son.
Keith G. Fairben, 24, lost his life while trying to save others injured in the worst terrorist attack in America on September 11, 2001. He responded to the call minutes after the first plane hit. The elder Fairben called his son on his cell phone: "Dad, I'm really busy. I am at the World Trade Center. I can't talk now." "Be careful", his father said, "Call us later." That was the last he heard from young Keith.
Keith Fairben worked for New York Presbyterian Hospital of New York City, New York. He had worked there as a medic going on four years. Keith had completed an 11-month EMT program at North Shore University Hospital in May 2001. He seemed to have a penchant for saving people. "I know when they find him, he will be with someone. He wouldn't abandon anyone," stated Keith's father.
No truer statement was ever made, that we are to bury our parents, not our children. Many parents have buried their children that were lost in the World Trade Center. However, what a beautiful legacy to quote, "He wouldn't abandon anyone."
Honored 2002
Keith Fairben New York Presbyterian Hospital New York, New York
As a father looks diligently through the rubble of the fallen World Trade Center, tears fall from the eyes of those around him. They can only grieve as they feel a small part of the pain he must feel within. The father, a volunteer firefighter for 32 years, is searching though the giant heap of twisted metal and sacred dust for a reason. He is looking for a victim lost in the fallen Twin Towers; however, not just any victim, he is looking for his only child, his son.
Keith G. Fairben, 24, lost his life while trying to save others injured in the worst terrorist attack in America on September 11, 2001. He responded to the call minutes after the first plane hit. The elder Fairben called his son on his cell phone: "Dad, I'm really busy. I am at the World Trade Center. I can't talk now." "Be careful", his father said, "Call us later." That was the last he heard from young Keith.
Keith Fairben worked for New York Presbyterian Hospital of New York City, New York. He had worked there as a medic going on four years. Keith had completed an 11-month EMT program at North Shore University Hospital in May 2001. He seemed to have a penchant for saving people. "I know when they find him, he will be with someone. He wouldn't abandon anyone," stated Keith's father.
No truer statement was ever made, that we are to bury our parents, not our children. Many parents have buried their children that were lost in the World Trade Center. However, what a beautiful legacy to quote, "He wouldn't abandon anyone."
Honored 2002
FW: Requested DocAlert: Smokeless Tobacco and Risk of Myocardial Infarction or Stroke: Systematic Review With Meta-Analysis
Smokeless Tobacco and Risk of Myocardial Infarction or Stroke: Systematic Review With Meta-Analysis
Dear Clinician,
Here is the information you requested (sourced from BMJ).
Published 18 August 2009, doi:10.1136/bmj.b3060
Cite this as: BMJ 2009;339:b3060
[Free full-text BMJ article (pdf)] [PubMed abstract]
Research
Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis
Paolo Boffetta, epidemiologist, Kurt Straif, epidemiologist
1 International Agency for Research on Cancer, Lyon, France
Correspondence to: P Boffetta, Genetics and Epidemiology Cluster, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France boffetta@iarc.fr
Objective To assess whether people who use smokeless tobacco products are at increased risk of myocardial infarction and stroke.
Design Meta-analysis of observational studies from Sweden and the United States.
Data sources Electronic databases and reference lists.
Data extraction Quantitative estimates of the association between use of smokeless tobacco products and risk of myocardial infarction and stroke among never smokers.
Review methods Both authors independently abstracted risk estimates and study characteristics. Summary relative risks were estimated on the basis of random effects models.
Results 11 studies, mainly in men, were included. Eight risk estimates were available for fatal myocardial infarction: the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence 1.06 to 1.21) and the excess risk was restricted to current users. The relative risk of fatal stroke, on the basis of five risk estimates, was 1.40 (1.28 to 1.54). The studies from both the United States and Sweden showed an increased risk of death from myocardial infarction and stroke. The inclusion of non-fatal myocardial infarction and non-fatal stroke lowered the summary risk estimates. Data on dose-response were limited but did not suggest a strong relation between risk of dying from either disease and frequency or duration of use of smokeless tobacco products.
Conclusion An association was detected between use of smokeless tobacco products and risk of fatal myocardial infarction and stroke, which does not seem to be explained by chance.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://imageb.epocrates.com/mailbot/links?EdID=42356822&LinkID=36943 and http://imageb.epocrates.com/mailbot/links?EdID=42356822&LinkID=48281.
© 2009 BMJ Publishing Group Ltd.
The above message comes from "BMJ", who is solely responsible for its content.
Monday, November 2, 2009
QOD
Which of the following is not a common complication
of an influenza infection?
a. Otitis media
b. Guillain-Barre syndrome
c. Bacterial pneumonia
d. Acute bronchitis
Numerous potential complications can stem from a primary influenza infection and contribute to the
initial presentation. An example might be the patient who presents with chest pain in the setting of a viral
respiratory illness and is found to have myocarditis as a complication of an influenza infection. Some of the
more common complications include acute bronchitis, bacterial pneumonia, and, in children, otitis media.
Answer: b
of an influenza infection?
a. Otitis media
b. Guillain-Barre syndrome
c. Bacterial pneumonia
d. Acute bronchitis
Numerous potential complications can stem from a primary influenza infection and contribute to the
initial presentation. An example might be the patient who presents with chest pain in the setting of a viral
respiratory illness and is found to have myocarditis as a complication of an influenza infection. Some of the
more common complications include acute bronchitis, bacterial pneumonia, and, in children, otitis media.
Answer: b
Sunday, November 1, 2009
QOD
Which of the following findings on transvaginal ultrasound is the first non-controversial and definitive sign in the initial diagnosis of an intrauterine pregnancy?
A. double decidual sign
B. intradecidual sign
C. pseudogestational sac
D. ring signE. yolk sac in the uterus
A double decidual sign is one of the first signs that is seen in an IUP and should be visualized 5 weeks after the last menstrual period. The double decidual sign is described as two echogenic rings surrounded by intrauterine fluid collection. (See Figure 1.) Caution should be taken, however, to differentiate this from a pseudogestational sac, which can be seen in ectopic pregnancy. This pseudogestational sac (see Figure 2) is due to a small amount of fluid being trapped within the endometrial canal, mimicking the appearance of the double decidual sign. Because of the risk of potential misinterpretation, there is controversy about using the double decidual sign to rule in an IUP.
The intradecidual sign is a linear echo in the uterine cavity in a pregnancy < 9 weeks in conjunction with a gestational sac or an echogenic area of early implantation located within a markedly thickened uterine cavity. (See Figure 3.) These findings may be mistaken for a decidual cyst or an endometrial cyst, which may coexist with ectopic pregnancy and makes the intradecidual sign controversial as a reliable finding for an IUP.
By 5.5 weeks from the last menstrual period, a yolk sac should be visualized within the gestational sac. (See Figure 4.) This is the earliest definitive sign of an intrauterine pregnancy. Gestations longer than 5.5 weeks have a visible IUP seen nearly 100% of the time. Operator expertise, however, decreases the sensitivity of TVU to 73-93%. If a definite IUP is seen and the patient is not at risk for heterotopic pregnancy (ectopic pregnancy and IUP), the patient does not have an ectopic pregnancy.
Diagnostic criteria for a tubal ectopic pregnancy on TVU include an empty endometrial cavity with either a heterogeneous adnexal mass (seen in approximately 60% of cases), an extra-uterine gestation sac with a yolk sac that may have a fetal pole +/- cardiac activity (seen in 13% of cases), or a ring sign. A ring sign is a mass in the adnexa with a hyperechoic ring around the gestational sac seen on TVU in approximately 20% of cases. (See Figure 5.) Diagnostic criteria for interstitial/cornual ectopic pregnancy include an empty endometrial cavity with a pregnancy visualized outside of the endometrial echo and surrounded by myometrium within the interstitial region.
Studies have shown that the overall sensitivity of TVU (TransVaginalUltrasound) for diagnosing ectopic pregnancy ranges between 74% and 98% and has a specificity of 99.9%. Patients with PUL on an initial TVU may in fact have an ectopic and should be followed closely.
In the event of rupture of the ectopic pregnancy, free fluid may be seen on TVU as an anechoic area around the uterus, in the pelvis or Morrison's pouch. (See Figure 6.)
Answer: E
A. double decidual sign
B. intradecidual sign
C. pseudogestational sac
D. ring signE. yolk sac in the uterus
A double decidual sign is one of the first signs that is seen in an IUP and should be visualized 5 weeks after the last menstrual period. The double decidual sign is described as two echogenic rings surrounded by intrauterine fluid collection. (See Figure 1.) Caution should be taken, however, to differentiate this from a pseudogestational sac, which can be seen in ectopic pregnancy. This pseudogestational sac (see Figure 2) is due to a small amount of fluid being trapped within the endometrial canal, mimicking the appearance of the double decidual sign. Because of the risk of potential misinterpretation, there is controversy about using the double decidual sign to rule in an IUP.
The intradecidual sign is a linear echo in the uterine cavity in a pregnancy < 9 weeks in conjunction with a gestational sac or an echogenic area of early implantation located within a markedly thickened uterine cavity. (See Figure 3.) These findings may be mistaken for a decidual cyst or an endometrial cyst, which may coexist with ectopic pregnancy and makes the intradecidual sign controversial as a reliable finding for an IUP.
By 5.5 weeks from the last menstrual period, a yolk sac should be visualized within the gestational sac. (See Figure 4.) This is the earliest definitive sign of an intrauterine pregnancy. Gestations longer than 5.5 weeks have a visible IUP seen nearly 100% of the time. Operator expertise, however, decreases the sensitivity of TVU to 73-93%. If a definite IUP is seen and the patient is not at risk for heterotopic pregnancy (ectopic pregnancy and IUP), the patient does not have an ectopic pregnancy.
Diagnostic criteria for a tubal ectopic pregnancy on TVU include an empty endometrial cavity with either a heterogeneous adnexal mass (seen in approximately 60% of cases), an extra-uterine gestation sac with a yolk sac that may have a fetal pole +/- cardiac activity (seen in 13% of cases), or a ring sign. A ring sign is a mass in the adnexa with a hyperechoic ring around the gestational sac seen on TVU in approximately 20% of cases. (See Figure 5.) Diagnostic criteria for interstitial/cornual ectopic pregnancy include an empty endometrial cavity with a pregnancy visualized outside of the endometrial echo and surrounded by myometrium within the interstitial region.
Studies have shown that the overall sensitivity of TVU (TransVaginalUltrasound) for diagnosing ectopic pregnancy ranges between 74% and 98% and has a specificity of 99.9%. Patients with PUL on an initial TVU may in fact have an ectopic and should be followed closely.
In the event of rupture of the ectopic pregnancy, free fluid may be seen on TVU as an anechoic area around the uterus, in the pelvis or Morrison's pouch. (See Figure 6.)
Answer: E
Saturday, October 31, 2009
CME
New York Presbyterian Hospital
Emergency Medical Services
Continuing Medical Education
NYP/Weill Cornell/Room M-107
Thursday November 5, 2009 4:00-8:00pm
NYP/Weill Cornell/Room M-107
Thursday November 5, 2009 4:00-8:00pm
Medical / Legal Considerations
With John Morrone, JD, MBA, NREMT-P
Andrew Leftt, JD
HIPPA/HITECH, EMTALA, Paramedic/EMT Liability, Ambulance Operations/MVTL, Federal Laws regarding healthcare, medical devices and FDA Law
With John Morrone, JD, MBA, NREMT-P
Andrew Leftt, JD
HIPPA/HITECH, EMTALA, Paramedic/EMT Liability, Ambulance Operations/MVTL, Federal Laws regarding healthcare, medical devices and FDA Law
If you have a question you would like to ask John,
Please E-mail it to me.
STEVE SAMUELS EMT-P
CME COORDINATOR
516-383-7248
SSAMUELS@OPTONLINE.NET
Please E-mail it to me.
STEVE SAMUELS EMT-P
CME COORDINATOR
516-383-7248
SSAMUELS@OPTONLINE.NET
Friday, October 30, 2009
PREP Act
Coverage Under the Public Readiness and Emergency Preparedness (PREP) Act for H1N1 Vaccination
What is the PREP Act?
The Public Readiness and Emergency Preparedness Act or PREP Act is a federal law that authorizes the Secretary of Health and Human Services to issue a declaration to provide tort liability immunity (except for willful misconduct) to individuals and organizations involved in the development, manufacture, distribution, administration and use of countermeasures against pandemics, epidemics and diseases and health threats caused by chemical, biological, radiological, or nuclear agents of terrorism.
How does the PREP Act work?
On June 15, 2009, Secretary of Health and Human Services Kathleen Sebelius extended the PREP Act declaration for pandemic vaccines to H1N1 vaccines, and amended the declaration on (date) to add provisions that can help H1N1vaccination campaigns.
What is tort liability immunity?
Tort liability immunity means that no legal tort claim related to activities described in the declaration that can be pursued in State or U.S. Federal court. The declaration provides legal liability protections for individuals or entities that are involved in the distribution and administration of H1N1 vaccine.
Who is immune from tort liability under H1N1 vaccine declaration?
The H1N1 vaccine declaration provides tort liability immunity to a group named “program planners.” Program planners include State and local governments, Tribes, other entities that supervise or administer a vaccination program, establish requirements, provide policy guidance, supply technical or scientific advice or assistance, or provide a facility to administer the vaccine. Program planners can include private sector individuals and organizations, community groups, schools, or businesses.
Government program planners only have tort liability immunity when the vaccines are provided to them voluntarily, such as when Federal Government provides vaccines from Federal stockpiles, or when the vaccines are donated or sold.
The H1N1 vaccine declaration also provides tort liability immunity to a group named “qualified persons.” Qualified persons include healthcare professionals or others authorized under State law to prescribe, administer, and dispense vaccines.
The declaration also provides tort liability immunity to individuals or organizations that assist public officials with vaccination programs, even if they are not licensed healthcare professionals. Qualified persons also include individuals or organizations (including their officials, agents, employees, contractors and volunteers) that are part of the public health and medical emergency response of the “Authority Having Jurisdiction” for prescribing, administering, delivering, distributing, or dispensing the vaccine following a declaration of emergency issued by a federal, regional, State, or local official. The “Authority Having Jurisdiction” is the public agency or entity or its delegate with legal responsibility and authority to respond to the incident. These qualified persons can include any public or private person, entity, or organization – such as local businesses, community groups and volunteer groups -- and their officials, agents, employees, contractors and volunteers, assisting in carrying out vaccine programs under agreements, plans, protocols, procedures, policies or other arrangements with any State, local or other public agency or its delegate that has legal responsibility and authority for public health and medical response. The Acting HHS Secretary’s April 26 declaration of nationwide public health emergency caused by H1N1, which was renewed by the HHS Secretary on July 24, can be used by “Authorities Having Jurisdiction” to begin their public health and medical response.
The H1N1 vaccine declaration also provides tort liability immunity to the United States, to vaccine manufacturers, and vaccine distributors.
Officials, agents, and employees of program planners, qualified persons, the United States, manufacturers, and distributors are also immune from tort liability.
Which vaccines are covered under the H1N1 vaccine declaration?
All of the H1N1 vaccine procured by the Department of Health and Human Services and distributed to the states is covered by the declaration.
Vaccines are covered only when they are administered and used as 1) licensed or approved by the Food and Drug Administration (FDA); 2) authorized for investigational use by the FDA; or 3) authorized under an Emergency Use Authorization (EUA) by the FDA. On September 15, 2008, the FDA approved four vaccines against H1N1 that are covered by the declaration.
What tort claims are prevented by the H1N1 vaccine declaration?
The declaration prevents tort liability claims under U.S. Federal law and State law (except for willful misconduct) for losses caused by, arising out of, relating to, or resulting from administration or use by any individual of the vaccine, including any claim with a causal relationship to any stage of development, distribution, dispensing, prescribing, administration or use of the vaccine.
Types of loss include death; physical, mental, or emotional injury, illness, disability or condition; fear of physical, mental, or emotional injury illness, disability, or condition, including any need for medical monitoring; and loss of or damage to property, including business interruption. In addition, by defining “administration” to include “delivery, distribution, and dispensing activities... and management and operation of distribution and dispensing locations” the H1N1 vaccine declaration clarifies that “slip and fall” types of claims are also covered, not just injuries and illnesses arising from actually receiving the vaccine.
What types of claims are not prevented by the H1N1 vaccine declaration?
The declaration does not prevent claims for willful misconduct. Willful misconduct is a term used in the PREP Act, and is beyond any standard of negligence or recklessness. Willful misconduct does not include acts or omissions by program planners and qualified persons who act consistently with the declarations, as long as they notify HHS or a State or local health authority within seven days of discovering any serious physical injury or death from the administration or use of the countermeasure.
The declaration also does not prevent other types of claims, such as claims for negligence in providing medical care unrelated to vaccine administration and use, claims brought under foreign law, or claims for civil rights or labor law violations.
What compensation is available for vaccine injuries?
The U.S. Department of Health and Human Services is establishing a Countermeasures Injury Compensation Program for H1N1 vaccines. Under this program, compensation may be available to eligible individuals who suffer serious physical injuries or death from administration of the vaccine under the declarations. Eligibility, and the types of injuries for which compensation may be available, will be defined by regulations. Compensation can include medical benefits, lost wages and death benefits.
Where can I go for more information?
For a copy of the PREP Act declaration for H1N1 vaccines, please go to: http://edocket.access.gpo.gov/2009/E9-14948.htm.
For more information about PREP Act liability protections, please go to http://www.hhs.gov/disasters/emergency/manmadedisasters/bioterorism/medication-vaccine-qa.html.
For more information about PREP Act Countermeasure Injury Compensation Program, please go to http://www.hrsa.gov/countermeasurescomp/default.htm.
For more information about the H1N1 vaccines approved by FDA, please go to http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181950.htm
Home| Frequent Questions| Contacting HHS| Accessibility| Privacy Policy| Freedom of Information Act| Disclaimers
What is the PREP Act?
The Public Readiness and Emergency Preparedness Act or PREP Act is a federal law that authorizes the Secretary of Health and Human Services to issue a declaration to provide tort liability immunity (except for willful misconduct) to individuals and organizations involved in the development, manufacture, distribution, administration and use of countermeasures against pandemics, epidemics and diseases and health threats caused by chemical, biological, radiological, or nuclear agents of terrorism.
How does the PREP Act work?
On June 15, 2009, Secretary of Health and Human Services Kathleen Sebelius extended the PREP Act declaration for pandemic vaccines to H1N1 vaccines, and amended the declaration on (date) to add provisions that can help H1N1vaccination campaigns.
What is tort liability immunity?
Tort liability immunity means that no legal tort claim related to activities described in the declaration that can be pursued in State or U.S. Federal court. The declaration provides legal liability protections for individuals or entities that are involved in the distribution and administration of H1N1 vaccine.
Who is immune from tort liability under H1N1 vaccine declaration?
The H1N1 vaccine declaration provides tort liability immunity to a group named “program planners.” Program planners include State and local governments, Tribes, other entities that supervise or administer a vaccination program, establish requirements, provide policy guidance, supply technical or scientific advice or assistance, or provide a facility to administer the vaccine. Program planners can include private sector individuals and organizations, community groups, schools, or businesses.
Government program planners only have tort liability immunity when the vaccines are provided to them voluntarily, such as when Federal Government provides vaccines from Federal stockpiles, or when the vaccines are donated or sold.
The H1N1 vaccine declaration also provides tort liability immunity to a group named “qualified persons.” Qualified persons include healthcare professionals or others authorized under State law to prescribe, administer, and dispense vaccines.
The declaration also provides tort liability immunity to individuals or organizations that assist public officials with vaccination programs, even if they are not licensed healthcare professionals. Qualified persons also include individuals or organizations (including their officials, agents, employees, contractors and volunteers) that are part of the public health and medical emergency response of the “Authority Having Jurisdiction” for prescribing, administering, delivering, distributing, or dispensing the vaccine following a declaration of emergency issued by a federal, regional, State, or local official. The “Authority Having Jurisdiction” is the public agency or entity or its delegate with legal responsibility and authority to respond to the incident. These qualified persons can include any public or private person, entity, or organization – such as local businesses, community groups and volunteer groups -- and their officials, agents, employees, contractors and volunteers, assisting in carrying out vaccine programs under agreements, plans, protocols, procedures, policies or other arrangements with any State, local or other public agency or its delegate that has legal responsibility and authority for public health and medical response. The Acting HHS Secretary’s April 26 declaration of nationwide public health emergency caused by H1N1, which was renewed by the HHS Secretary on July 24, can be used by “Authorities Having Jurisdiction” to begin their public health and medical response.
The H1N1 vaccine declaration also provides tort liability immunity to the United States, to vaccine manufacturers, and vaccine distributors.
Officials, agents, and employees of program planners, qualified persons, the United States, manufacturers, and distributors are also immune from tort liability.
Which vaccines are covered under the H1N1 vaccine declaration?
All of the H1N1 vaccine procured by the Department of Health and Human Services and distributed to the states is covered by the declaration.
Vaccines are covered only when they are administered and used as 1) licensed or approved by the Food and Drug Administration (FDA); 2) authorized for investigational use by the FDA; or 3) authorized under an Emergency Use Authorization (EUA) by the FDA. On September 15, 2008, the FDA approved four vaccines against H1N1 that are covered by the declaration.
What tort claims are prevented by the H1N1 vaccine declaration?
The declaration prevents tort liability claims under U.S. Federal law and State law (except for willful misconduct) for losses caused by, arising out of, relating to, or resulting from administration or use by any individual of the vaccine, including any claim with a causal relationship to any stage of development, distribution, dispensing, prescribing, administration or use of the vaccine.
Types of loss include death; physical, mental, or emotional injury, illness, disability or condition; fear of physical, mental, or emotional injury illness, disability, or condition, including any need for medical monitoring; and loss of or damage to property, including business interruption. In addition, by defining “administration” to include “delivery, distribution, and dispensing activities... and management and operation of distribution and dispensing locations” the H1N1 vaccine declaration clarifies that “slip and fall” types of claims are also covered, not just injuries and illnesses arising from actually receiving the vaccine.
What types of claims are not prevented by the H1N1 vaccine declaration?
The declaration does not prevent claims for willful misconduct. Willful misconduct is a term used in the PREP Act, and is beyond any standard of negligence or recklessness. Willful misconduct does not include acts or omissions by program planners and qualified persons who act consistently with the declarations, as long as they notify HHS or a State or local health authority within seven days of discovering any serious physical injury or death from the administration or use of the countermeasure.
The declaration also does not prevent other types of claims, such as claims for negligence in providing medical care unrelated to vaccine administration and use, claims brought under foreign law, or claims for civil rights or labor law violations.
What compensation is available for vaccine injuries?
The U.S. Department of Health and Human Services is establishing a Countermeasures Injury Compensation Program for H1N1 vaccines. Under this program, compensation may be available to eligible individuals who suffer serious physical injuries or death from administration of the vaccine under the declarations. Eligibility, and the types of injuries for which compensation may be available, will be defined by regulations. Compensation can include medical benefits, lost wages and death benefits.
Where can I go for more information?
For a copy of the PREP Act declaration for H1N1 vaccines, please go to: http://edocket.access.gpo.gov/2009/E9-14948.htm.
For more information about PREP Act liability protections, please go to http://www.hhs.gov/disasters/emergency/manmadedisasters/bioterorism/medication-vaccine-qa.html.
For more information about PREP Act Countermeasure Injury Compensation Program, please go to http://www.hrsa.gov/countermeasurescomp/default.htm.
For more information about the H1N1 vaccines approved by FDA, please go to http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181950.htm
Home| Frequent Questions| Contacting HHS| Accessibility| Privacy Policy| Freedom of Information Act| Disclaimers
Subscribe to:
Posts (Atom)
